Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SARS-CoV-2 vaccine - EpiVax/University of Georgia

Drug Profile

SARS-CoV-2 vaccine - EpiVax/University of Georgia

Alternative Names: COVID-19 vaccine

Latest Information Update: 20 Mar 2020

At a glance

  • Originator EpiVax; University of Georgia
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 04 Mar 2020 EpiVax and University of Georgia collaborate to develop COVID-19 vaccine
  • 04 Mar 2020 Early research in COVID-2019 infections (Prevention) in USA (unspecified route)

Development Overview

Introduction

A vaccine is being developed by EpiVax and University of Georgia for the prevention of prevention of COVID-19 infections caused due to coronavirus (SARS-CoV-2). EpiVax is applying its vaccine re-engineering approach to identify the key regions of viral sequences that should be included in vaccines to keep individuals safe from infection, while excluding other sequences that make the vaccine less effective or safe. Early research is ongoing in the US.

Company Agreements

In March 2020, EpiVax entered onto a collaboration agreement with University of Georgia to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine. Financial terms of the agreement were not disclosed. [1]

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E9 (All other viral vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research USA unspecified / unspecified EpiVax, University of Georgia 04 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
University of Georgia Originator USA
EpiVax Originator USA
University of Georgia Owner USA
EpiVax Owner USA

Development History

Event Date Update Type Comment
04 Mar 2020 Licensing Status EpiVax and University of Georgia collaborate to develop COVID-19 vaccine [1] Updated 20 Mar 2020
04 Mar 2020 Phase Change Early research in COVID-2019 infections (Prevention) in USA (unspecified route) [1] Updated 20 Mar 2020

References

  1. EpiVax Accelerates COVID-19 Vaccine Development with UGA's Center for Vaccines and Immunology.

    Media Release
Back to top